PL3398946T3 - Sól pochodnej morfolinowej i jej postać krystaliczna, jak również sposób jej wytwarzania, kompozycja farmaceutyczna i jej zastosowanie - Google Patents
Sól pochodnej morfolinowej i jej postać krystaliczna, jak również sposób jej wytwarzania, kompozycja farmaceutyczna i jej zastosowanieInfo
- Publication number
- PL3398946T3 PL3398946T3 PL16881245.1T PL16881245T PL3398946T3 PL 3398946 T3 PL3398946 T3 PL 3398946T3 PL 16881245 T PL16881245 T PL 16881245T PL 3398946 T3 PL3398946 T3 PL 3398946T3
- Authority
- PL
- Poland
- Prior art keywords
- salt
- preparation
- well
- pharmaceutical composition
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511016783 | 2015-12-29 | ||
| PCT/CN2016/112966 WO2017114456A1 (zh) | 2015-12-29 | 2016-12-29 | 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3398946T3 true PL3398946T3 (pl) | 2022-10-10 |
Family
ID=59224612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16881245.1T PL3398946T3 (pl) | 2015-12-29 | 2016-12-29 | Sól pochodnej morfolinowej i jej postać krystaliczna, jak również sposób jej wytwarzania, kompozycja farmaceutyczna i jej zastosowanie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10519150B2 (pl) |
| EP (1) | EP3398946B1 (pl) |
| JP (1) | JP6818031B2 (pl) |
| CN (3) | CN113816952A (pl) |
| DK (1) | DK3398946T3 (pl) |
| ES (1) | ES2918674T3 (pl) |
| HU (1) | HUE059444T2 (pl) |
| PL (1) | PL3398946T3 (pl) |
| PT (1) | PT3398946T (pl) |
| TW (1) | TWI705065B (pl) |
| WO (1) | WO2017114456A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114129569A (zh) * | 2020-09-04 | 2022-03-04 | 上海医药集团股份有限公司 | 一种含氮的饱和杂环化合物的应用 |
| WO2022047730A1 (en) * | 2020-09-04 | 2022-03-10 | Shanghai Pharmaceuticals Holding Co., Ltd. | Methods to treat inflammatory bowel disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003519698A (ja) * | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ，インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
| MX349484B (es) * | 2011-03-16 | 2017-07-31 | Mitsubishi Tanabe Pharma Corp | Compuesto heterocíclico saturado que contiene nitrógeno. |
| CN104640847B (zh) * | 2012-09-14 | 2019-10-15 | 上海医药集团股份有限公司 | 新型肾素抑制剂 |
| JP5764628B2 (ja) * | 2012-09-14 | 2015-08-19 | 田辺三菱製薬株式会社 | 医薬組成物 |
-
2016
- 2016-12-29 CN CN202110801274.0A patent/CN113816952A/zh active Pending
- 2016-12-29 CN CN201611246909.0A patent/CN106928218B/zh active Active
- 2016-12-29 ES ES16881245T patent/ES2918674T3/es active Active
- 2016-12-29 US US16/066,490 patent/US10519150B2/en active Active
- 2016-12-29 TW TW105143910A patent/TWI705065B/zh active
- 2016-12-29 PL PL16881245.1T patent/PL3398946T3/pl unknown
- 2016-12-29 DK DK16881245.1T patent/DK3398946T3/da active
- 2016-12-29 WO PCT/CN2016/112966 patent/WO2017114456A1/zh active Application Filing
- 2016-12-29 PT PT168812451T patent/PT3398946T/pt unknown
- 2016-12-29 HU HUE16881245A patent/HUE059444T2/hu unknown
- 2016-12-29 CN CN202110794158.0A patent/CN113816951B/zh active Active
- 2016-12-29 EP EP16881245.1A patent/EP3398946B1/en active Active
- 2016-12-29 JP JP2018534034A patent/JP6818031B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3398946A4 (en) | 2019-08-28 |
| EP3398946A1 (en) | 2018-11-07 |
| CN113816951B (zh) | 2022-09-27 |
| CN113816952A (zh) | 2021-12-21 |
| CN113816951A (zh) | 2021-12-21 |
| CN106928218B (zh) | 2021-08-03 |
| DK3398946T3 (da) | 2022-08-08 |
| JP6818031B2 (ja) | 2021-01-20 |
| TW201722950A (zh) | 2017-07-01 |
| TWI705065B (zh) | 2020-09-21 |
| HUE059444T2 (hu) | 2022-11-28 |
| CN106928218A (zh) | 2017-07-07 |
| WO2017114456A1 (zh) | 2017-07-06 |
| US20190016718A1 (en) | 2019-01-17 |
| US10519150B2 (en) | 2019-12-31 |
| ES2918674T3 (es) | 2022-07-19 |
| JP2019500385A (ja) | 2019-01-10 |
| EP3398946B1 (en) | 2022-05-04 |
| PT3398946T (pt) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1243999A1 (zh) | 新型3-吲哚取代的衍生物、藥物組合物及使用方法 | |
| HK1231377A1 (zh) | 包含喹啉衍生物或其鹽的藥物組合物及其製備方法 | |
| IL247062A0 (en) | Heterocyclic compounds, their preparation and pharmaceutical preparations containing them | |
| HK1243424A1 (zh) | 4'-硫代核苷的新型化合物及其製備方法、藥物組合物和應用 | |
| HK1231416A1 (zh) | 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物 | |
| HK1220965A1 (zh) | 鹽、相關的晶體形式、其製備方法以及含有其的藥物組合物 | |
| ZA201805600B (en) | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | |
| HRP20200104T8 (hr) | Novi heterociklični spoj, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto | |
| HUP1500618A2 (en) | Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them | |
| IL258977B (en) | Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them | |
| EP3284743A4 (en) | Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof | |
| PL3398946T3 (pl) | Sól pochodnej morfolinowej i jej postać krystaliczna, jak również sposób jej wytwarzania, kompozycja farmaceutyczna i jej zastosowanie | |
| ME03727B (me) | Zamjena za so i njena primena | |
| IL254597A0 (en) | Crystalline form of ahu377, method for its preparation and use | |
| GB2559718B (en) | Novel crystalline form of tribenuron-methyl, process for preparation and use thereof | |
| EP3175851A4 (en) | Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition | |
| ZA201803722B (en) | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof | |
| HUP1400519A2 (hu) | Gyógyászati készítmény elõállítására alkalmazható laquinimod kristályforma és laquinimod nátrium só kristályforma | |
| HUP1600269A2 (hu) | Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei | |
| PL3061765T3 (pl) | Pochodna protoescygeniny, sposób jej otrzymywania, zastosowanie i użycie w kompozycjach farmaceutycznych zawierających ten związek | |
| HUP1400520A2 (hu) | Gyógyászati készítmény elõállítására alkalmazható laquinimod sók |